Skip to main content
main-content

13-12-2019 | Breast cancer | Video

SABCS 2019 | KEYNOTE-522 shows pembrolizumab–chemotherapy benefit across subgroups

Peter Schmid presents subgroup analyses from the KEYNOTE-522 trial of neoadjuvant and adjuvant pembrolizumab in patients with early-stage triple-negative breast cancer (4:54).

Funding for independent interviews at SABCS 2019 was provided by F. Hoffmann-La Roche Ltd, Basel, Switzerland.

See the research in context now

with trial summaries, expert opinion and congress coverage

Image Credits